New figures show Cyprus outperforming EU averages in prostate, breast, colorectal and lung cancer survival.
Cancer patients in Cyprus are achieving survival outcomes that surpass the European Union average for several of the most common forms of the disease, according to figures presented during a press conference held by biopharmaceutical company Bristol Myers Squibb.
The data, shared by specialists from the German Oncology Center in Limassol, show that Cyprus records particularly strong results in prostate, breast, colorectal and lung cancer survival.
Medical oncologist Dr Georgios Orphanos said survival rates in Cyprus reach 99 per cent for prostate cancer, compared with 87 per cent across the EU. Breast cancer survival stands at 93 per cent against an EU average of 83 per cent, while colorectal cancer survival reaches 72 per cent compared with 60 per cent. For lung cancer, the rate is 19 per cent, exceeding the European figure of 15 per cent.
Dr Orphanos attributed the results to prompt diagnosis and advances in modern cancer treatments. He stressed that prevention programmes and early detection remain essential factors in improving patient outcomes.
The role of coordinated specialist care was also discussed during the event. Dr Konstantinos Zampoglou, radiation oncologist and medical director of the German Oncology Center, said multidisciplinary teams help develop personalised treatment plans, monitor patients throughout their care and provide psychological support.
Experts attending the conference also reviewed recent developments in the treatment of lung cancer, gastrointestinal cancers and melanoma. Presentations focused on the growing contribution of immunotherapy and targeted therapies in extending survival and improving quality of life for patients.
According to the organisers, the event also examined the importance of following established treatment guidelines and basing clinical decisions on the strongest available scientific evidence.
Participants pointed to the value of timely access to innovative medicines, cooperation between different medical specialties and a comprehensive approach to cancer care.
